Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23558430 | 0.78 | PGR (0.39) | TBK1PGRCDC7CCNE1CDK2 | |
| SCHEMBL6200142 | 0.68 | MAPT (0.49) | PGRPDE3BPDE3A | |
| SCHEMBL23524349 | 0.67 | S1PR1 (0.44) | TBK1PGRCDC7CCNE1CDK2 | |
| SCHEMBL25864140 | 0.66 | XDH (0.45) | TBK1PGRXDH | |
| SCHEMBL23558399 | 0.66 | CTSC (0.35) | S1PR1XDH | |
| SCHEMBL23558463 | 0.65 | S1PR1 (0.59) | S1PR1 | |
| SCHEMBL29771163 | 0.63 | S1PR1 (0.44) | TBK1PGRCDC7CCNE1CDK2 | |
| SCHEMBL23084622 | 0.63 | S1PR1 (0.44) | TBK1PGRCDC7CCNE1CDK2 | |
| SCHEMBL23523860 | 0.63 | S1PR1 (0.46) | TBK1PGRS1PR1 | |
| SCHEMBL18189409 | 0.61 | GRIA1 (0.66) | PGRPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | TBK1 1937/4885PGR 1551/4885CDC7 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.